Ivankiv (UA)
{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~58 mi. (Kyiv, Ukraine, +89 more cities)
facility
Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, +2 more facilities
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
giredestrant, +1 more drug
drug type
hormone therapy
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~58 mi. (Kyiv, Ukraine, +144 more cities)
facility
Kyiv City Clinical Oncology Center ( Site 2706)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~58 mi. (Kyiv, Ukraine, +226 more cities)
facility
Municipal non-profit enterprise Kyiv City Clinical Oncology -Oncourology department ( Site 1204)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~58 mi. (Kyiv, Ukraine, +140 more cities)
facility
Shalimov s NI of Surgery and Transplantation ( Site 0671)
condition
Hepatocellular Carcinoma
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~58 mi. (Kyiv, Ukraine, +199 more cities)
facility
Shalimov s NI of Surgery and Transplantation ( Site 0781)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~58 mi. (Kyiv, Ukraine, +207 more cities)
facility
Kyiv City Clinical Oncology Centre ( Site 2716)
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~58 mi. (Kyiv, Ukraine, +159 more cities)
facility
Kyiv City Clinical Oncology Center ( Site 0960)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~58 mi. (Kyiv, Ukraine, +163 more cities)
facility
Kyiv City Clinical Oncology Center ( Site 0960)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~58 mi. (Kyiv, Ukraine, +158 more cities)
facility
National Cancer Institute of the MoH of Ukraine ( Site 2101), +2 more facilities
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~58 mi. (Kyiv, Ukraine, +122 more cities)
facility
Clinic of National Cancer Institute ( Site 2101), +2 more facilities
condition
Small Cell Lung Carcinoma
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types